Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Social Media Site Could Help FDA Track Adverse Events

Executive Summary

FDA-pharma partnership could improve data quality and increase use as industry continues to struggle to incorporate social media into pharmacovigilance.

You may also be interested in...

PDUFA VI: Breakthrough Issues Among FDA Priorities

Agency and industry also decide to drop research into using social media to enhance post-market safety monitoring.

PDUFA VI: FDA Proposes Expanding Sentinel, Real-World Safety Data Sources

Growth of post-market surveillance system also may require more resources.

To Improve Adverse Event Tracking, FDA Could Google It

Teleconference between Google and FDA signals the internet search giant could have a way to improve adverse-event detection. The agency calls the talk “a high-level, general discussion” of Google’s capabilities.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts